CD8A and colorectal carcinoma: Its derivative, OBP-502, has been shown to induce ICD in models of CRC and pancreatic ductal adenocarcinoma (PDAC), functioning synergistically with PD-1 blockade to promote CD8+ T cell infiltration and enhance systemic antitumor immunity (144).